A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy

Trial Profile

A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Icotinib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ICOGEN
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 02 Jun 2017 Results (n=352) of updated analysis evaluating the ability of blood based proteomic test to predict outcomes in Icotinib treated patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results (n=357) of retrospective analysis demonstrating the utility of VeriStrat in a Chinese cohort treated with EGFR TKI presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 12 Aug 2013 Results published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top